Yannis Hamidou | Immunotherapy |

Published on by Top Pharmaceutical

Mr. Yannis Hamidou | Immunotherapy | Best Researcher Award

Yannis Hamidou at Amiens Picardie University Hospital | France

Mr. Yannis Hamidou is a dedicated rheumatologist currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, France. With a strong academic background in medical sciences, rheumatology, and sports medicine, he has actively contributed to clinical research focusing on autoimmune and inflammatory diseases. His expertise spans therapeutic innovations, patient-centered care, and multidisciplinary collaborations aimed at improving outcomes in rheumatology and intensive care settings. Through his clinical practice and research endeavors, Mr. Hamidou has developed a reputation for excellence in precision treatment strategies and evidence-based medicine, significantly impacting rheumatology healthcare and contributing to advancements in patient management practices.

Publication Profile 

Orcid

Education 

Mr. Yannis Hamidou completed his postgraduate diploma in medical sciences, laying the foundation for his medical career. He successfully defended his medical thesis , advancing his academic and clinical expertise. To specialize further, he obtained a postgraduate diploma in rheumatology, focusing on autoimmune and inflammatory disorders. Additionally, he completed a specialization in sports medicine and earned the BPC certification, broadening his clinical competencies. This comprehensive academic training has equipped him with extensive knowledge across internal medicine, rheumatology, and sports-related healthcare, preparing him for leadership roles in clinical care, research, and education.

Experience 

Mr. Yannis Hamidou is currently serving as Clinic Chief Assistant at CHU Amiens-Picardie, where he integrates clinical care with research responsibilities. His work in intensive care medicine includes serving as Principal Investigator for an observational clinical study, focusing on chronic inflammatory diseases in critical care settings. Alongside his clinical duties, he actively participates in developing patient-specific treatment strategies for autoimmune and rheumatologic disorders. His multidisciplinary experience spans rheumatology, sports medicine, and internal medicine, providing comprehensive care solutions. He also contributes to academic teaching and mentoring, fostering evidence-based clinical practices while engaging in ongoing research aimed at improving patient outcomes.

Awards and Honors 

Mr. Yannis Hamidou academic achievements and clinical leadership reflect his professional excellence. His appointments, including Clinic Chief Assistant at CHU Amiens-Picardie and Principal Investigator roles in clinical studies, highlight his recognition within the medical community. His selection for advanced training in rheumatology, sports medicine, and critical care research further emphasizes his commitment to advancing medical science. Future recognitions are anticipated as his contributions to rheumatology research, patient care innovations, and academic scholarship continue to grow, positioning him as a promising leader in the field of rheumatology and clinical medicine in France.

Research Focus 

Mr. Yannis Hamidou research primarily targets autoimmune and inflammatory disorders, with a focus on therapeutic innovations and patient outcome optimization. His work in rheumatology explores the long-term maintenance of advanced therapies like Janus kinase inhibitors and investigates biomarkers such as fecal calprotectin for early disease detection. Additionally, he has contributed to understanding mortality causes in intensive care settings among patients with chronic inflammatory diseases. By integrating real-world data and observational clinical research, his studies aim to refine diagnostic precision, enhance treatment strategies, and inform evidence-based clinical guidelines, ultimately improving healthcare delivery for patients with complex rheumatologic conditions.

Publication Top Notes

Denise Faustman | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Denise Faustman | Immunotherapy | Best Researcher Award

Associate Professor of Medicine at Harvard Medical School  | United States

Dr. Denise Faustman is a physician-scientist recognized for her pioneering work in immunology, autoimmunity, and type 1 diabetes research. She serves as Director of the Immunobiology Laboratory at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. Her career bridges clinical medicine, molecular biology, and translational research, with a focus on advancing novel therapies for autoimmune diseases. Dr. Faustman has significantly contributed to understanding immune tolerance, vaccine-based interventions, and the role of BCG vaccination in autoimmune modulation. She is widely respected for her leadership, scientific advisory roles, and commitment to women’s health and immunological innovation.

Publication Profile 

Scopus

Education

Dr. Denise Faustman earned a B.S. in Zoology and Chemistry from the University of Michigan, followed by an M.D. and Ph.D. in Molecular and Cellular Biology from Washington University School of Medicine in St. Louis. She completed her postdoctoral training in transplantation immunology at Washington University before pursuing clinical training in internal medicine and endocrinology at Massachusetts General Hospital and Harvard Medical School. Her combined training in medicine, molecular biology, and immunology has uniquely positioned her to integrate clinical insights with advanced laboratory science, fueling her translational research on autoimmunity, immunotherapy, and novel strategies for the treatment of chronic diseases.

Experience 

Dr. Denise Faustman has built a distinguished career at Harvard Medical School and Massachusetts General Hospital, where she directs the Immunobiology Laboratory. Her academic roles span from Instructor to Associate Professor of Medicine, combined with leadership in clinical and translational immunology. She has served on numerous national and international scientific committees, including advisory roles at the FDA, NIH, NAS, and Institute of Medicine. As a physician-scientist, she bridges patient care with laboratory innovation, advancing novel treatments for autoimmune diseases. She has also provided scientific leadership for biotech companies, foundations, and research councils, shaping biomedical policy, discovery, and translational impact.

Awards and Honors 

Dr. Denise Faustman contributions have been recognized through prestigious appointments and leadership roles. She has served as Chair and Board Member of the Society for Women’s Health Research, Advisory Committee Member for the FDA, and Chair of national immunology and autoimmunity symposia. She has been elected to scientific advisory boards for biotechnology companies and foundations worldwide, including Sjögren’s Syndrome Foundation and Farallone Therapeutics. Her expertise has been sought by NASA, NIH, and the Department of Defense for defining priorities in immunology, vaccine safety, and women’s health. These roles reflect her influence, innovation, and leadership in advancing immunological and biomedical sciences.

Research Focus 

Dr. Denise Faustman research centers on autoimmunity, immune regulation, and translational immunotherapy. Her laboratory is internationally recognized for pioneering studies on immune tolerance and the use of BCG vaccine as a potential therapy for type 1 diabetes. She investigates mechanisms of T cell regulation, biomarkers for autoimmune progression, and pathways of immune modulation to translate discoveries into clinical applications. Her work bridges fundamental immunology with patient-centered research, aiming to develop safe, effective, and durable treatments for chronic autoimmune diseases. By integrating laboratory science, clinical trials, and translational medicine, Dr. Faustman is shaping innovative therapeutic strategies with global health impact.

Publication Top Notes

The spleen assumes a major role in blood glucose regulation in type 1 diabetes patients treated with BCG

Late in the US pandemic, multi-dose BCG vaccines protect against COVID-19 and infectious diseases

Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer

Association of BCG Vaccine Treatment with Death and Dementia in Patients with Non-Muscle-Invasive Bladder Cancer

TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4+Foxp3+ regulatory T cells

Letter to the Editor Regarding “The Non-Significant Benefit of BCG Vaccination for the Treatment of Iranian Patients with Type 1 Diabetes up to 48 Weeks: A Controversial Result”

The benefits of clustering in TNF receptor superfamily signaling

Bacille Calmette Guerin (BCG) and prevention of types 1 and 2 diabetes: Results of two observational studies

BCG vaccinations drive epigenetic changes to the human T cell receptor: Restored expression in type 1 diabetes

Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes

Rulla Tamimi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Rulla Tamimi | Immunotherapy | Best Researcher Award

Dr. Rulla Tamimi at Weill Cornell Medicine Dept of Healthcar, United States.

Dr. Rulla M. Tamimi is a leading cancer epidemiologist and Professor of Population Health Sciences and Pathology at Weill Cornell Medicine. With over two decades of experience in breast cancer research, her work centers on cancer risk prediction, environmental exposures, and molecular epidemiology. A pioneer in integrating biomarkers and epidemiologic data, she has advanced understanding of breast cancer heterogeneity and disparities. Dr. Tamimi is also a principal investigator for multiple NIH-funded studies and a dedicated educator. She plays a critical role in shaping future public health strategies and improving women’s health through rigorous research and community-engaged science.

Publication Profile 

Scopus

Education

Dr. Tamimi holds a B.S. in Biology from Tufts University (1993), followed by an M.S. (1999) and Sc.D. (2003) in Epidemiology from the Harvard T.H. Chan School of Public Health. Her academic training is rooted in public health, statistical methods, and cancer epidemiology. She received advanced training at Harvard, which set the stage for a prolific research and academic career in molecular and clinical epidemiology. Her education enabled her to translate complex biological mechanisms into population-level cancer prevention strategies, and her leadership has consistently bridged rigorous epidemiological research with patient-focused public health innovation.

Experience

Dr. Tamimi has held prestigious academic positions including Instructor, Assistant Professor, Associate Professor at Harvard Medical School and Harvard T.H. Chan School of Public Health (2003–2020). She currently serves as Professor at Weill Cornell Medicine (2020–Present). With over 20 years in academic medicine, she’s also served as Associate Epidemiologist at Brigham and Women’s Hospital. Dr. Tamimi leads NIH- and NCI-funded multi-institutional projects, mentoring future epidemiologists while advancing cancer research. She has contributed to global education through lectures and program direction across institutions including Boston University, Harvard, and National University of Singapore.

Awards 

Dr. Tamimi has received multiple accolades for her visionary research. She earned the “Good Questions Meet Big Data” Ideation Challenge Award from Harvard Catalyst in 2017 and became a Susan G. Komen Scholar in 2020. Her election to prominent organizations such as the American Association for Cancer Research, Society for Epidemiologic Research, and Cornell Center for Health Equity highlights her influence in the field. These recognitions reflect her leadership in molecular epidemiology, commitment to health equity, and significant contributions to cancer prevention research on both national and global scales.

Research Focus 

Dr. Tamimi’s research explores breast cancer heterogeneity, environmental exposures, and the biological underpinnings of cancer risk. Her projects evaluate how dietary carotenoids, genetic variants, circulating metabolites, and breast tissue markers influence cancer outcomes. She is especially interested in aggressive tumor subtypes, breast cancer in young women, and disparities across racial and socioeconomic lines. Current studies also examine stromal contributions to carcinogenesis and social determinants of health through the SoCa Center. Her work connects molecular biology with epidemiological insights to improve early detection, prevention, and personalized treatment strategies for breast cancer.

Publication Top Notes

  • Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
  • Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts
  • Disparities in adherence to guideline-concordant care and receipt of immunotherapy for Non-Small cell lung cancer in the United States
  • Thromboembolic Events Are Increased After Splenectomy in Postmenopausal Women
  • The Breast Tumor Immune Microenvironment of DNA Double-Strand Break Repair Pathogenic Variant Carriers Is Enriched with Tumor-Associated Macrophages
  • The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause
  • Associations of alcohol consumption with expression of CD44, CD24, and ALDH1A1 stem cell markers in benign breast biopsy samples
  • Breast cancer prevention by short-term inhibition of TGFβ signaling
  • Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses’ health study
  • A genome-wide association study of mammographic texture variation

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Published on by Top Pharmaceutical

Efthalia Zervoudi | Immunotherapy | Best Researcher Award

Dr. Efthalia Zervoudi, Hellenic Pasteur Institute, Greece

Dr. Efthalia Zervoudi is a senior researcher at the Hellenic Pasteur Institute with a PhD in Biochemistry from the University of Athens. Her research focuses on designing inhibitors targeting antigen-trimming aminopeptidases, contributing significantly to immunology and cancer biology. She has extensive experience in oncology and molecular biomarkers, having held positions at Cardiff University and University Hospital “Attikon.” Dr. Zervoudi has authored multiple influential publications and holds patents on aminopeptidase inhibitors. She has received prestigious fellowships, including the Welcome Trust ISSF fellowship, and continues to advance personalized medicine through innovative molecular diagnostic approaches.

Publication Profile

Google Scholar

Education

I completed my PhD in Biochemistry at the University of Athens (2012–2016) with top honors, focusing on designing inhibitors targeting antigen-trimming aminopeptidases. Before that, I earned my Master’s degree in Biochemistry from the same university (2010–2012), studying the specificity pockets of aminopeptidases involved in antigen processing. My academic journey began with a Bachelor’s degree in Chemistry from the University of Patras (2003–2008), where I researched proteoglycans in cancer patients under Prof. Dimitrios Vynios. 🎓 Prior to university, I graduated high school with a strong average score of 18.5/20, marking the start of my scientific path.

Experience

Dr. Efthalia Zervoudi is currently serving as a Senior Researcher at the Hellenic Pasteur Institute (2024–present), contributing to cutting-edge biomedical research. From 2019 to 2023, she was a Research Coordinator at the Oncology Unit of University Hospital “Attikon” in Greece. 🏥 Previously, she held a postdoctoral research position at Cardiff University’s School of Medicine (2016–2019), specializing in Infection and Immunity. 🔬 Between 2010 and 2015, she collaborated with the Protein Chemistry Lab at the National Centre for Scientific Research “DEMOKRITOS”, working on the project: “Rational design and development of inhibitors for targeting antigen-trimming aminopeptidases.”

Awards

Dr. Efthalia Zervoudi has received several prestigious fellowships and awards recognizing her impactful research. In 2020, she was awarded funding by the Hellenic Society of Oncology for her study on Endoplasmic Reticulum Associated Peptidases as tools to understand cancer. 🧪 In 2015, she received the esteemed Wellcome Trust ISSF Fellowship at Cardiff University. 🇬🇧 Earlier, in Fall 2014, the Hellenic Academy of Athens honored her with the “Axillea and Aikaterini Dionysopoulou” award for her groundbreaking work on rationally designed inhibitors enhancing antigen presentation and cytotoxic T-cell responses. 🔬🎖️ Her research continues to push scientific boundaries.

Research Focus

Dr. Efthalia Zervoudi is a leading researcher in immunology and molecular biology, with a focus on antigen processing, immune regulation, and aminopeptidase function. Her work explores how enzymes like ERAP1 and ERAP2 trim antigenic peptides for presentation by MHC class I molecules, enhancing cytotoxic T-cell responses—a crucial process in cancer immunotherapy and autoimmune disease research. 🧬 She also develops targeted inhibitors to modulate immune responses, contributing to vaccine design and tumor immunity. 🧪 Her research bridges biochemistry, structural biology, and immuno-oncology, with potential applications in personalized medicine.

Publication Top Notes

Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses

Probing the S1 specificity pocket of the aminopeptidases that generate antigenic peptides

A common single nucleotide polymorphism in endoplasmic reticulum aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

Optimized peptide–MHC multimer protocols for detection and isolation of autoimmune T-cells

A role for naturally occurring alleles of endoplasmic reticulum aminopeptidases in tumor immunity and cancer pre-disposition

Autoimmune disease-associated variants of extracellular endoplasmic reticulum aminopeptidase 1 induce altered innate immune responses by human immune cells

3, 4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties

Novel selective inhibitors of aminopeptidases that generate antigenic peptides

Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope

A common SNP in ER aminopeptidase 2 induces a specificity switch that leads to altered antigen processing

HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway

Correction: Konstantopoulos et al. HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression through a miR-143/HIF-1a Pathway. Viruses 2024, 16, 113

Dr. Annie Zhang|Immunotherapy|Best Researcher Award

Published on by Top Pharmaceutical

Dr. Annie Zhang|Immunotherapy|Best Researcher Award

Dr. Annie Zhang at Cambridge,United States

PROFILE  

 

Scopus

Dr. Annie Zhang embarked on her academic journey with a strong foundation in medicine and public health, earning an MD and an MPH. Her dual degrees equipped her with a nuanced understanding of clinical medicine and the critical public health frameworks essential for managing and preventing diseases at both population and individual levels. Driven by a commitment to advancing therapeutic options and improving patient outcomes, she honed her knowledge in both biostatistics and epidemiology. These skills have been foundational throughout her career, particularly in her roles focused on evidence generation and clinical research.

🌟 Professional Endeavors

Throughout her distinguished career, Dr. Zhang has held senior roles at prominent pharmaceutical companies, demonstrating her expertise in medical affairs, clinical research, and strategic evidence generation.

  1. Sanofi, Cambridge, MA
    As the Global Senior Medical Director in Immunology & Dermatology since 2018, Dr. Zhang has led impactful initiatives in Medical Evidence Generation within Global Medical Affairs. Her key achievements include winning Sanofi’s “Best of Best” award in 2023 and receiving a 1st Place Poster award at the American Academy of Dermatology (AAD) conference in 2024 for her work’s scientific importance. Her leadership has propelled Sanofi’s immunology initiatives, particularly through studies such as PEDISTAD and INFANTSTAD, which focus on disease modification and prevention of the atopic march.
  2. Apellis, Waltham, MA
    In her tenure as Medical Director at Apellis from January 2017 to December 2017, Dr. Zhang was responsible for strategic planning and clinical development in hematology, overseeing Phase II and III studies in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia (AIHA). Her role included extensive interaction with thought leaders and the clinical team to design and optimize trial strategies.
  3. Biogen, Cambridge, MA
    From 2009 to 2016, Dr. Zhang held several pivotal roles at Biogen, advancing from Medical Director in Global Medical Affairs to leading biostatistical teams for key drug programs like Tecfidera. She worked on Tysabri’s lifecycle management, supporting clinical trial design, data generation, and publication strategies, especially in multiple sclerosis (MS). Her expertise in biostatistics and clinical research design strengthened Biogen’s data-driven approaches, particularly in Phase III and IV clinical trials.
  4. PAREXEL International, Lowell, MA
    Dr. Zhang worked as a Senior Biostatistician at PAREXEL from 2007 to 2009, leading biostatistical tasks across diverse therapeutic areas, including oncology, CNS disorders, and cardiovascular disease. Her meticulous approach ensured the quality and accuracy of statistical reports for clinical trials, contributing to numerous successful projects within the biostatistics team.
  5. New England Research Institutes, Watertown, MA
    Early in her career, Dr. Zhang served as an Associate Research Scientist at NERI from 2000 to 2007, where she conducted critical statistical analyses for clinical research, laying the groundwork for her later expertise in biostatistics and clinical study design.

💡 Contributions and Research Focus

Dr. Zhang’s research has centered around dermatology, immunology, and hematology. At Sanofi, her work in immunology has led to groundbreaking insights on skin barrier integrity and neuroimmune function, providing essential evidence for the prevention of atopic march. She has also driven significant advancements in real-world evidence generation, particularly in cross-functional collaboration with global market access and regulatory teams, demonstrating her strategic alignment with organizational goals and patient needs.

🏆 Accolades and Recognition

Dr. Zhang’s achievements have earned her numerous accolades, including the prestigious “Best of Best” award at Sanofi in 2023. In addition, she received 1st Place at the AAD 2024 Poster Award for her study on skin barrier health. Her work has also made her one of the most-read and cited authors in Allergy and Pediatric Dermatology in 2024, underscoring her impact and visibility in her field.

🌐 Impact and Influence

Through her extensive collaborations, Dr. Zhang has influenced clinical practices and regulatory frameworks worldwide. Her involvement in key study proposals and evidence generation initiatives has significantly impacted the medical community’s understanding of dermatological conditions. Her efforts in strategic planning, data generation, and cross-functional teamwork have positioned her as an influential figure in dermatology and immunology, particularly in advancing therapies that meet rigorous safety and efficacy standards.

🌱 Legacy and Future Contributions

Dr. Zhang’s legacy lies in her innovative approach to medical evidence generation and her unwavering commitment to patient-centered research. Her leadership in studies such as PEDISTAD and INFANTSTAD has set new standards for clinical research in dermatology and immunology. As she continues her work at Sanofi, Dr. Zhang’s contributions promise to expand the understanding and treatment of complex immunological conditions, impacting healthcare practices on a global scale.

Through her career, Dr. Zhang has exemplified excellence, dedication, and a strategic vision, ensuring her place as a respected leader in the pharmaceutical and clinical research sectors. Her ongoing work will undoubtedly continue to shape medical innovations and patient care improvements, leaving a lasting legacy in the fields of immunology and dermatology.

🎓Publication 

Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM

  • Authors   :Fox, R.J., Gold, R., Phillips, J.T., … Zhang, A., Marantz, J.L.
  • Journal    :Neurology and Therapy
  • Year         :2017

Number Needed to Treat in Multiple Sclerosis Clinical Trials

  • Authors   : Okwuokenye, M., Zhang, A., Pace, A., Peace, K.E.
  • Journal    :Neurology and Therapy
  • Year         :2017

Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis

  • Authors   : Fox, R.J., Chan, A., Zhang, A., … Edwards, M.R., Marantz, J.L
  • Journal    :Current Medical Research and Opinion
  • Year         :2017

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

  • Authors   :Gold, R., Giovannoni, G., Phillips, J.T., … Zhang, A., Marantz, J.L.
  • Journal    :Neurology and Therapy
  • Year         :2016

Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS

  • Authors   :Spelman, T., Kalincik, T., Jokubaitis, V., … Trojano, M., Butzkueven, H.
  • Journal    :Neurology: Clinical Practice
  • Year         :2016

Dr. Marc Bender|Immunotherapy |Best Researcher Award

Published on by Top Pharmaceutical

Dr. Marc Bender|Pharmaceutical Chemistry |Best Researcher Award|

Dr. Marc Bender at abriz University of Medical Sciences, Iran

PROFILE  

orcid

Early Academic Pursuits 📚

Marc Bender’s academic journey began with a strong foundation in molecular biology, earning a (link unavailable) and (link unavailable) from Universität Hamburg. He furthered his expertise by pursuing a doctorate in skin cancer research at the department of dermatology, Elbe Klinikum Buxtehude. His thesis focused on elucidating molecular mechanisms, particularly epigenetic regulation via miRNAs, involved in tumor progression of cutaneous squamous cell carcinoma.

Professional Endeavors 💼

As a data scientist, Marc contributed to the European melanoma registry (EUMelaReg), evaluating retrospective data for real-world clinical trials. This experience deepened his understanding of melanoma and immunotherapy, and he developed skills in statistical methods and programming. His professional endeavors have been marked by a commitment to advancing cancer research and treatment.

Contributions and Research Focus 🔬

Marc’s research focus encompasses various aspects of skin cancer, including:

– Investigating effects of combined UVA, UVB, visible light, and infrared radiation on human skin cells (KAUVIR)
– Examining the influence of UVA and UVB irradiation on human dermal stem cells (UV-DHDS)
– Comparing treatments for melanoma, including anti-PD1 monotherapy and BRAF/MEK inhibitor treatment (PDSeq and EMRSeq)
– Analyzing immune checkpoint inhibitor maintenance treatment after achieving a partial or complete response (EUMelaReg)

Accolades and Recognition 🏆

Marc’s work has been recognized through publications in esteemed journals, including:

– Journal of Cancer Research and Clinical Oncology
– Journal of Photochemistry and Photobiology B Biology
– Cancers (MDPI)
– Journal of Clinical Oncology (conference paper)
– Annals of Oncology (conference paper)

Impact and Influence 🌟

Marc’s research has contributed significantly to the understanding of skin cancer mechanisms and treatment options. His work has:

– Advanced knowledge of miRNA expression and its association with tumor progression
– Investigated treatment adherence in patients with stage III melanoma
– Compared outcomes of different treatment approaches for metastatic melanoma

Legacy and Future Contributions 🌱

As a dedicated researcher, Marc continues to contribute to the field of skin cancer research. His future endeavors will likely focus on:

– Furthering understanding of molecular mechanisms in skin cancer
– Developing innovative treatment approaches
– Collaborating with international researchers to advance cancer research

Marc’s legacy will be marked by his commitment to advancing cancer research, improving treatment options, and enhancing patient outcomes. His work will continue to influence the scientific community, inspiring future generations of researchers.

🎓Publication 

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany

  • Authors   : Marc Bender
  • Journal    :Cancers
  • Year         :2022

UVB damage response of dermal stem cells as melanocyte precursors compared to keratinocytes, melanocytes, and fibroblasts from human foreskin

  • Authors   :Marc Bender
  • Journal    :Photochemistry and Photobiology B: Biology
  • Year         :2021

UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines

  • Authors   : Marc Bender
  • Journal    :Cancer Research and Clinical Oncologyy
  • Year         :2020